Accueil / Tag Archives: Webcast (page 20)

Tag Archives: Webcast

Cerus Corporation Announces Record Second Quarter 2019 Results

Thursday, August 1st 2019 at 8:01pm UTC CONCORD, Calif.–(BUSINESS WIRE)– Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2019. Recent developments and highlights include: Total second quarter revenue of $22.5 million Record quarterly product revenue of $18.2 million, an 18% increase compared to …

Plus »

Columbia Care to Present at the Canaccord Genuity 39th Annual Growth Conference

Thursday, August 1st 2019 at 11:30am UTC NEW YORK–(BUSINESS WIRE)– Columbia Care, Inc. (NEO:CCHW) (OTCQX:CCHWF) (FSE:3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, today announced that Nicholas Vita, co-founder and chief executive …

Plus »

Five Prime Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call

Thursday, August 1st 2019 at 1:16am UTC SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. …

Plus »

Charles River Laboratories Announces Second-Quarter 2019 Results

Wednesday, July 31st 2019 at 11:00am UTC – Second-Quarter Revenue of $657.6 Million – – Second-Quarter GAAP Earnings per Share of $0.88 and Non-GAAP Earnings per Share of $1.63 – – Updates 2019 Guidance – WILMINGTON, Mass.–(BUSINESS WIRE)– Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for …

Plus »

GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

Thursday, August 1st 2019 at 11:30am UTC Announced completion of enrollment in Pfizer’s Phase 3 clinical trial evaluating rivipansel, the Company’s lead investigational drug candidate, in sickle cell disease (SCD) Enrolled first patient in National Cancer Institute (NCI)-sponsored Phase 3 clinical trial of uproleselan in older adults with previously untreated …

Plus »

CONMED Corporation Announces Second Quarter 2019 Financial Results

Wednesday, July 31st 2019 at 8:01pm UTC UTICA, N.Y.–(BUSINESS WIRE)– CONMED Corporation (Nasdaq: CNMD) today announced financial results for the second quarter of 2019. Second Quarter 2019 Highlights Sales of $238.3 million increased 12% year over year as reported and 12.8% in constant currency. Acquisitions contributed approximately 630 basis points …

Plus »

Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Thursday, August 1st 2019 at 11:31am UTC Enrollment Initiated in Phase 2 Trial Cohort Evaluating SY-1425 and Azacitidine in Genomically Defined Patients with Relapsed or Refractory Acute Myeloid Leukemia Multiple Clinical Data Readouts Expected for SY-1425 and SY-1365 in 2019 and 2020 Management to Host Conference Call at 8:30 a.m. …

Plus »

Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

Thursday, August 1st 2019 at 12:00pm UTC BEDFORD, Mass.–(BUSINESS WIRE)– Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside …

Plus »

Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Wednesday, July 31st 2019 at 8:06pm UTC – Total Revenue of $240.3 Million, Cabozantinib Franchise Revenue of $193.7 Million – – GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.29 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.